364 related articles for article (PubMed ID: 28277540)
21. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer.
Manderson EN; Presneau N; Provencher D; Mes-Masson AM; Tonin PN
Mol Carcinog; 2002 Jun; 34(2):78-90. PubMed ID: 12112314
[TBL] [Abstract][Full Text] [Related]
23. Limited importance of the dominant-negative effect of TP53 missense mutations.
Stoczynska-Fidelus E; Szybka M; Piaskowski S; Bienkowski M; Hulas-Bigoszewska K; Banaszczyk M; Zawlik I; Jesionek-Kupnicka D; Kordek R; Liberski PP; Rieske P
BMC Cancer; 2011 Jun; 11():243. PubMed ID: 21668955
[TBL] [Abstract][Full Text] [Related]
24. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
25. Coordination of TP53 abnormalities in breast cancer: data from analysis of TP53 polymorphisms, loss of heterozygosity, methylation, and mutations.
Denisov EV; Sukhanovskaya TV; Dultseva TS; Malinovskaya EA; Litviakov NV; Slonimskaya EM; Choinzonov EL; Cherdyntseva NV
Genet Test Mol Biomarkers; 2011 Dec; 15(12):901-7. PubMed ID: 21810023
[TBL] [Abstract][Full Text] [Related]
26. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment.
Alexandrova EM; Yallowitz AR; Li D; Xu S; Schulz R; Proia DA; Lozano G; Dobbelstein M; Moll UM
Nature; 2015 Jul; 523(7560):352-6. PubMed ID: 26009011
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
28. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
[TBL] [Abstract][Full Text] [Related]
29. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
[TBL] [Abstract][Full Text] [Related]
30. The Gain-of-Function p53 R248W Mutant Promotes Migration by STAT3 Deregulation in Human Pancreatic Cancer Cells.
Klemke L; Fehlau CF; Winkler N; Toboll F; Singh SK; Moll UM; Schulz-Heddergott R
Front Oncol; 2021; 11():642603. PubMed ID: 34178628
[TBL] [Abstract][Full Text] [Related]
31. High metastatic potential in mice inheriting a targeted p53 missense mutation.
Liu G; McDonnell TJ; Montes de Oca Luna R; Kapoor M; Mims B; El-Naggar AK; Lozano G
Proc Natl Acad Sci U S A; 2000 Apr; 97(8):4174-9. PubMed ID: 10760284
[TBL] [Abstract][Full Text] [Related]
32. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
33. Mutant p53 gain of function induces HER2 over-expression in cancer cells.
Román-Rosales AA; García-Villa E; Herrera LA; Gariglio P; Díaz-Chávez J
BMC Cancer; 2018 Jul; 18(1):709. PubMed ID: 29970031
[TBL] [Abstract][Full Text] [Related]
34. Analysis for loss of heterozygosity (LOH) of p53 allele in tumors derived from p53+/- and CD-1 mice following repeated subcutaneous injections of solutions containing antioxidants.
Youssef AF; Borellini F; Jacobson-Kram D; Fort FL
Environ Mol Mutagen; 2001; 37(1):27-30. PubMed ID: 11170239
[TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
36. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
37. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
38. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
39. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
40. Gain-of-Function p53 Mutation Acts as a Genetic Switch for TGFβ Signaling-Induced Epithelial-to-Mesenchymal Transition in Intestinal Tumors.
Wang D; Nakayama M; Hong CP; Oshima H; Oshima M
Cancer Res; 2024 Jan; 84(1):56-68. PubMed ID: 37851521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]